Ergomed completed the acquisition of ADAMAS for $35m.

Ergomed, a company focused on providing specialised services to the pharmaceutical industry, completed the acquisition of ADAMAS, a regulatory compliance provider, for $35m. “This value-enhancing acquisition aligns with our disciplined M&A strategy, strengthening our position as a focussed premium pharmaceutical services business, whilst further building our Group’s scale in the strategically important US, Europe and APAC regions. With this deal we are addressing the pharmaceutical industry’s ever-growing need for best practice quality assurance due to the increasing complexity of drug development, pharmacovigilance and manufacturing processes and associated regulatory requirements. We look forward to working with Ian and the ADAMAS management team as we invest in and support this business to deliver a broader service offering to clients," Miroslav Reljanović, Ergomed Executive Chairman.